TapewireFind a company

person · Reporting owner

Landsittel Michael

Disclosed activity across 2 companies

Tapewire entity
55999
SEC CIK
0001651036

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Damora Therapeutics, Inc.DMRA · Entity 4602DirectorMarch 23, 2026March 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Damora Therapeutics, Inc.

Report date March 23, 2026 · Filed March 25, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.05 · Expires 2036-03-23Direct37,313 Reported balance After 2026-03-23 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2026-03-23 · Grant · Acquired 37,313 · Balance 37,313

F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Blueprint Medicines Corp

Report date July 17, 2025 · Filed July 21, 2025

Section 16 reporting ended · disclosed 2025-07-21. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Ending reported balance After 2025-07-17 transaction · row 3
3 source rows · reconciled sequence

Row 1 · 2025-07-17 · Grant · Acquired 21,353 · Balance 94,277

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

Row 2 · 2025-07-17 · Disposition to issuer · Disposed 51,102 · Balance 43,175

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

Row 3 · 2025-07-17 · Other · Disposed 43,175 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.01Direct0 Reported balance After 2025-07-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · 2025-07-17 · Disposition to issuer · Disposed 10,000 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.44Direct0 Reported balance After 2025-07-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2025-07-17 · Disposition to issuer · Disposed 26,000 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.60Direct0 Reported balance After 2025-07-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2025-07-17 · Disposition to issuer · Disposed 19,500 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.13Direct0 Reported balance After 2025-07-17 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2025-07-17 · Disposition to issuer · Disposed 25,000 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.13Direct0 Reported balance After 2025-07-17 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2025-07-17 · Disposition to issuer · Disposed 26,125 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $61.31Direct0 Reported balance After 2025-07-17 transaction · row 9 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 9 · 2025-07-17 · Disposition to issuer · Disposed 25,000 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.15Direct0 Reported balance After 2025-07-17 transaction · row 10 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 10 · 2025-07-17 · Disposition to issuer · Disposed 25,000 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $95.12Direct0 Reported balance After 2025-07-17 transaction · row 11 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 11 · 2025-07-17 · Disposition to issuer · Disposed 25,000 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $96.57Direct0 Reported balance After 2025-07-17 transaction · row 12 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 12 · 2025-07-17 · Disposition to issuer · Disposed 22,000 · Balance 0

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

F5: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

F6: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 23, 2026 Filed Mar 25, 2026 18:05 UTC Damora Therapeutics, Inc. DMRA · Entity 4602 GrantStock Option (right to buy) · Derivative 37,313 $0.00 Strike: $23.05 $0.00
Disclosure

SEC source: 0001193125-26-124476 · ownership.xml · derivative · entry 1

Landsittel Michael · CIK 0001651036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,313

Underlying: Common Stock · 37,313 shares

Expires 2036-03-23

F1 · derivative.exercise_date: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through March 23, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 22,000 Not disclosed Strike: $96.57 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 12

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 22,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $95.12 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 11

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $43.15 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 10

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $61.31 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 9

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 26,125 Not disclosed Strike: $100.13 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 8

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,125 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 25,000 Not disclosed Strike: $54.13 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 7

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 19,500 Not disclosed Strike: $86.60 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 6

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 19,500 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 26,000 Not disclosed Strike: $81.44 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 5

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerStock Option (Right to Buy) · Derivative 10,000 Not disclosed Strike: $15.01 Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · derivative · entry 4

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires not disclosed

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F6 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 OtherCommon Stock 43,175 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · nonDerivative · entry 3

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F5 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 Disposition to issuerCommon Stock 51,102 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,175

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3 · price: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

Read SEC document
July 17, 2025 Filed Jul 21, 2025 19:50 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantCommon Stock 21,353 Not disclosed Not disclosed
Disclosure

SEC source: 0001104659-25-069396 · tm2521348-12_4seq1.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,277

F1 · kind: This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

F2 · kind: Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

F3 · price: Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

Read SEC document
March 05, 2025 Filed Mar 7, 2025 16:10 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 5,284 $88.80 $469,219.20
Disclosure

SEC source: 0001415889-25-007392 · form4-03072025_090343.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,924

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 17:17 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantStock Option (Right to Buy) · Derivative 22,000 $0.00 Strike: $96.57 $0.00
Disclosure

SEC source: 0001415889-25-006603 · form4-03042025_100306.xml · derivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2035-02-28

F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2025 and as to an additional 1/48th of the shares underlying the option each month thereafter.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 17:17 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantCommon Stock 11,000 $0.00 $0.00
Disclosure

SEC source: 0001415889-25-006603 · form4-03042025_100306.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,208

F1 · shares: The reported transaction involved the Reporting Person's receipt of a grant of 11,000 restricted stock units under the Issuer's 2024 Stock Incentive Plan.

Read SEC document
August 15, 2024 Filed Aug 19, 2024 16:00 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 4,409 $95.23 $419,869.07
Disclosure

SEC source: 0001415889-24-021550 · form4-08192024_040802.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 67,208

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $94.80 to $95.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this form 4.

Read SEC document
May 15, 2024 Filed May 17, 2024 16:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 1,364 $106.56 $145,347.84
Disclosure

SEC source: 0001415889-24-013469 · form4-05172024_040510.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 71,617

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.23 to $106.86 per share.

Read SEC document
May 15, 2024 Filed May 17, 2024 16:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 2,486 $107.17 $266,424.62
Disclosure

SEC source: 0001415889-24-013469 · form4-05172024_040510.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 72,981

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.94 to $107.88 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (3) in this form 4.

Read SEC document
May 08, 2024 Filed May 10, 2024 16:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionStock Option (Right to Buy) · Derivative 1,818 $0.00 Strike: $8.80 $0.00
Disclosure

SEC source: 0001415889-24-012843 · form4-05102024_040507.xml · derivative · entry 4

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,818 shares

Expires 2024-10-08

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The options were granted on October 8, 2014 and are fully vested as of the transaction date.

Read SEC document
May 08, 2024 Filed May 10, 2024 16:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionStock Option (Right to Buy) · Derivative 26,363 $0.00 Strike: $1.87 $0.00
Disclosure

SEC source: 0001415889-24-012843 · form4-05102024_040507.xml · derivative · entry 3

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 26,363 shares

Expires 2025-02-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The options were granted on February 10, 2015 and are fully vested as of the transaction date.

Read SEC document
May 08, 2024 Filed May 10, 2024 16:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionCommon Stock 1,818 $8.80 $15,998.40
Disclosure

SEC source: 0001415889-24-012843 · form4-05102024_040507.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 75,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction involved a cash exercise of options without a subsequent sale of the underlying shares of common stock.

Read SEC document
May 08, 2024 Filed May 10, 2024 16:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionCommon Stock 26,363 $1.87 $49,298.81
Disclosure

SEC source: 0001415889-24-012843 · form4-05102024_040507.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,649

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction involved a cash exercise of options without a subsequent sale of the underlying shares of common stock.

Read SEC document
May 02, 2024 Filed May 6, 2024 17:26 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionStock Option (Right to Buy) · Derivative 10,000 $0.00 Strike: $36.05 $0.00
Disclosure

SEC source: 0001415889-24-012359 · form4-05062024_090549.xml · derivative · entry 3

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,000 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the transaction date.

Read SEC document
May 02, 2024 Filed May 6, 2024 17:26 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 10,000 $105.00 $1,050,000.00
Disclosure

SEC source: 0001415889-24-012359 · form4-05062024_090549.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,286

F1 · kind: Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
May 02, 2024 Filed May 6, 2024 17:26 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionCommon Stock 10,000 $36.05 $360,500.00
Disclosure

SEC source: 0001415889-24-012359 · form4-05062024_090549.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 16:34 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $36.05 $0.00
Disclosure

SEC source: 0001415889-24-009536 · form4-04012024_080444.xml · derivative · entry 3

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 5,000 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the transaction date.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 16:34 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 5,000 $95.00 $475,000.00
Disclosure

SEC source: 0001415889-24-009536 · form4-04012024_080444.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,286

F1 · kind: Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
March 28, 2024 Filed Apr 1, 2024 16:34 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionCommon Stock 5,000 $36.05 $180,250.00
Disclosure

SEC source: 0001415889-24-009536 · form4-04012024_080444.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 52,286

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected through a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
March 15, 2024 Filed Mar 19, 2024 17:11 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionStock Option (Right to Buy) · Derivative 5,000 $0.00 Strike: $36.05 $0.00
Disclosure

SEC source: 0001415889-24-008593 · form4-03192024_090315.xml · derivative · entry 8

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 5,000 shares

Expires 2027-02-16

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F8 · derivative.exercise_date: This option was granted on February 16, 2017 and is fully vested as of the transaction date.

Read SEC document
March 15, 2024 Filed Mar 19, 2024 17:11 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 2,467 $88.94 $219,414.98
Disclosure

SEC source: 0001415889-24-008593 · form4-03192024_090315.xml · nonDerivative · entry 7

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,286

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.81 to $89.27 per share.

Read SEC document
March 15, 2024 Filed Mar 19, 2024 17:11 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 1,638 $88.08 $144,275.04
Disclosure

SEC source: 0001415889-24-008593 · form4-03192024_090315.xml · nonDerivative · entry 6

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 49,753

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.75 to $88.72 per share.

Read SEC document
March 15, 2024 Filed Mar 19, 2024 17:11 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 4,629 $87.09 $403,139.61
Disclosure

SEC source: 0001415889-24-008593 · form4-03192024_090315.xml · nonDerivative · entry 5

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,391

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.58 to $87.42 per share.

Read SEC document
March 15, 2024 Filed Mar 19, 2024 17:11 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 912 $88.88 $81,058.56
Disclosure

SEC source: 0001415889-24-008593 · form4-03192024_090315.xml · nonDerivative · entry 4

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,020

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.79 to $89.26 per share.

Read SEC document
March 15, 2024 Filed Mar 19, 2024 17:11 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 1,413 $88.27 $124,725.51
Disclosure

SEC source: 0001415889-24-008593 · form4-03192024_090315.xml · nonDerivative · entry 3

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,932

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.75 to $88.71 per share.

Read SEC document
March 15, 2024 Filed Mar 19, 2024 17:11 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 2,675 $87.10 $232,992.50
Disclosure

SEC source: 0001415889-24-008593 · form4-03192024_090315.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,345

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $86.65 to $87.63 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (7).

Read SEC document
March 15, 2024 Filed Mar 19, 2024 17:11 UTC Blueprint Medicines Corp BPMC · Entity 77326 Exercise / conversionCommon Stock 5,000 $36.05 $180,250.00
Disclosure

SEC source: 0001415889-24-008593 · form4-03192024_090315.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 61,020

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Effected pursuant to a trading plan adopted on December 6, 2023 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.

Read SEC document
March 07, 2024 Filed Mar 11, 2024 18:23 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 5,003 $90.69 $453,722.07
Disclosure

SEC source: 0001415889-24-007557 · form4-03112024_100313.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,020

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 16:17 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $95.12 $0.00
Disclosure

SEC source: 0001415889-24-007010 · form4-03062024_090319.xml · derivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2034-03-01

F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2024 and as to an additional 1/48th of the shares underlying the option each month thereafter.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 16:17 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantCommon Stock 12,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-24-007010 · form4-03062024_090319.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 61,023

F1 · balance_after: The reported transaction involved the Reporting Person's receipt of grant of 12,500 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan.

Read SEC document
March 06, 2023 Filed Mar 8, 2023 21:26 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 96 $44.48 $4,270.08
Disclosure

SEC source: 0001415889-23-004557 · form4-03092023_020319.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,523

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $43.97 to $44.78 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 06, 2023 Filed Mar 8, 2023 21:26 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 2,911 $45.72 $133,090.92
Disclosure

SEC source: 0001415889-23-004557 · form4-03092023_020319.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,619

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 20:12 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $43.15 $0.00
Disclosure

SEC source: 0001415889-23-004264 · form4-03042023_010349.xml · derivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2033-03-01

F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2023 and as to an additional 1/48th of the shares underlying the option each month thereafter.

Read SEC document
March 01, 2023 Filed Mar 3, 2023 20:12 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantCommon Stock 12,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-23-004264 · form4-03042023_010349.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,530

F1 · balance_after: The reported transaction involved the Reporting Person's receipt of grant of 12,500 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan.

Read SEC document
March 07, 2022 Filed Mar 8, 2022 16:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 1,047 $56.19 $58,830.93
Disclosure

SEC source: 0001415889-22-002735 · form4-03082022_040318.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,030

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $56.18 to $57.13 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

Read SEC document
March 03, 2022 Filed Mar 8, 2022 16:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 1,328 $60.27 $80,038.56
Disclosure

SEC source: 0001415889-22-002735 · form4-03082022_040318.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,077

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 20:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantStock Option (Right to Buy) · Derivative 25,000 $0.00 Strike: $61.31 $0.00
Disclosure

SEC source: 0001415889-22-002438 · form4-03032022_050310.xml · derivative · entry 2

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2032-03-01

F2 · derivative.exercise_date: This option vests with respect to 1/48th of the shares underlying the option on April 1, 2022 and as to an additional 1/48th of the shares underlying the option each month thereafter.

Read SEC document
March 01, 2022 Filed Mar 3, 2022 20:05 UTC Blueprint Medicines Corp BPMC · Entity 77326 GrantCommon Stock 12,500 $0.00 $0.00
Disclosure

SEC source: 0001415889-22-002438 · form4-03032022_050310.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · CHIEF FINANCIAL OFFICER

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,405

F1 · balance_after: The reported transaction involved the Reporting Person's receipt of grant of 12,500 restricted stock units under Issuer's 2015 Stock Option and Incentive Plan.

Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:51 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 1,411 $86.61 $122,206.71
Disclosure

SEC source: 0001179110-21-003010 · edgar.xml · nonDerivative · entry 2

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,905

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

Read SEC document
March 04, 2021 Filed Mar 5, 2021 17:51 UTC Blueprint Medicines Corp BPMC · Entity 77326 SaleCommon Stock 96 $88.98 $8,542.08
Disclosure

SEC source: 0001179110-21-003010 · edgar.xml · nonDerivative · entry 1

Landsittel Michael · CIK 0001651036 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,316

F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.84 to $89.31 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.